ACUTE ISCHEMIC STROKE IN WOMEN: EFFICACY OF THE FREE RADICAL SCAVENGER EDARAVONE

The aim: To investigate the effectiveness of usage of the free radical scavenger Edaravone in the therapy of women with AIS. Materials and methods: A prospective study was conducted of 48 women with AIS, divided into two groups. Patients in the first group (n = 36) were treated with edaravone 30 mg twice a day intravenously. Neuroprotectors were not used in the control group (n = 12). Clinical-instrumental and neurological examination (Glasgow scale (SCG), FOUR, NIHSS, and neuronspecific enolase (NSE) levels) were performed on all patients. Results: The mean FOUR score in the 1th group increased from 11.04±0.85 to 15.47±0.63 points against 11.39±0.56 to 13.46±1.49 in the control group (p<0.05). The level of NSE in control group patients increased 10-fold (from 9.2 to 96.4 ng/ml, p<0.01). Subsequently, there was a rapid decrease in NSE level in 1th group, and in the control group until 10 days of treatment, the level of NSE did not reach the reference values (p <0.05). Conclusions: The introduction of edaravone in women with AIS results in positive results already in the acute period of the disease. The use of edaravon was significantly effective on the FOUR scale and the dynamics of NSE levels.

Serum level of neuronspecific enolase in chronic neuroimmune inflammation

.

Neurospecific enolase as a nonspecific neurodegenerative process marker

For the diagnosis and prognosis of various diseases is essential to determine specific markers in blood serum. Neuronspecific enolase (NSE) is a common marker of differentiatedneurons. The aim of the study was to evaluate the activity of NSE in patients with Parkinson's disease (PD) and chronic cerebral ischemia. The study results showed that the activity of NSE varied dependingon sex and age in PD patients, the stage and rate of progression of disease, age debut and severity of cognitive impairment. Thus, determination of NSE in the serum of PD patients should be included in the complex examination of patients with PD, as an additional marker of the neurodegenerative process.